amended claims is attached as Appendix A. A clean set of the pending claims is attached as Appendix B. Claims 1, 6-7, 10, 14-15, and 22 were amended to clarify the claim language. Claims 4, 7, 10, and 14-15 were amended to clarify the claimed range. Applicants intend to claim from "about" or approximately the lower limit to about the upper limit. Although as filed this was clear to one of ordinary skill in the art, Applicants wish to merely clarify the claim language. No change to the scope of any of the amended claims is intended by these amendments. New claims 36-37 replace canceled claims 11-12. No new matter has been added by way of these amendments, such that their entry at this time is warranted.

Applicants believe all claims to be in condition for allowance, early notice of which would be appreciated. Should the Examiner not agree, then a personal or telephone interview is respectfully requested to discuss and resolve any remaining issues to expedite allowance of this application.

No fee is believed to be due for this response. Should any fees be required, please charge such fees to Winston & Strawn deposit account no. 501-814.

Respectfully submitted,

August 19, 2002
Date

Matthew R. Osenga (Reg. No. 45,600)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN
Customer No. 28765

202-371-5780

APPENDIX A: MARKED UP VERSION OF THE AMENDED CLAIMS

1. (Amended) An endometriosis or infertility treating, or fertility improving pharmaceutical composition comprising [of]:

(i) a therapeutically effective amount of a β-adrenergic agonist [for the purpose of treating endometriosis or infertility, or for improving fertility], and

(ii) a pharmaceutically acceptable bioadhesive carrier.

4. (Amended) The composition of claim 3, wherein the concentration of terbutaline is [from less than] about 0.1% to about 0.4% weight/weight.

6. (Amended) An endometriosis or infertility treating, or fertility improving, pharmaceutical composition comprising [of] a therapeutically effective amount of a β-adrenergic agonist [for the purpose of treating endometriosis or infertility, or for improving fertility, while avoiding detrimental blood levels of β-adrenergic agonist].

7. (Amended) The composition of claim 6, wherein the β-adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage [of about 0.5 to 2.5 g., which] that delivers [from less than] about 1 mg. to about 8 mg. of terbutaline.

10. (Amended) The composition of claim 9 [wherein the composition is] formulated to be administered in a dosage [of about 1.0 to 1.5 g, which] that delivers [from less than] about 2 mg to about 4 mg of terbutaline.

14. (Amended) The method of claim 13, wherein the β-adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage [of about 0.5 to 2.5 g., which] that delivers [from less than] about 1 mg. to about 8 mg. of terbutaline.

15. (Amended) The method of claim 14, wherein the composition is administered in a dosage [of about 1.0 to 1.5 g, which] that delivers [from less than] about 2 mg to about 4 mg of terbutaline.

22. (Twice amended) The method of claim 15, wherein the composition [further comprises] is administered in the form of a tablet.